Clinical Research Directory

Inclusion Criteria: * ECOG performance status 0 or 1; * Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; * Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months; * For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the "four-factor model"; * Bone marrow function: white blood cell (WBC) count ≥3.0×10⁹/L, neutrophil count (NEUT) ≥1.5×10⁹/L, platelet count (PLT) ≥80×10⁹/L, hemoglobin (Hb) ≥90 g/L; renal function: normal or serum creatinine (SCr) ≤1.5×upper limit of normal (ULN) or creatinine clearance ≥50 ml/min; hepatic function: total bilirubin (TBIL) ≤1.5×ULN, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5×ULN; * Voluntarily signed the informed consent form prior to study enrollment. Exclusion Criteria: * History of active malignant tumor within 3 years prior to initial treatment（except for the cervical cancer）and any locally curable tumors treated with radical therapy; * Any high-risk factor confirmed by postoperative pathology: positive lymph node metastasis, positive parametrial invasion, or positive resection margin; * History of neoadjuvant therapy prior to enrollment; * Local recurrence or distant metastasis prior to enrollment; * Postoperative intestinal obstruction or intestinal adhesion; * Severe cardiac, cerebral, hepatic, or renal disorders; * Long-term immunocompromised state; * Pregnant or lactating females; * Premature discontinuation of treatment for any reason; * Poor compliance, unwillingness to participate, or inability to cooperate with follow-up; * Any other conditions deemed unsuitable for this trial by the investigator.